Trial Profile

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Farletuzumab ecteribulin (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Eisai Inc

09 Dec 2024 Planned End Date changed from 30 Oct 2024 to 31 Dec 2024.
09 Dec 2024 Planned primary completion date changed from 30 Oct 2024 to 31 Dec 2024.
31 Oct 2024 Planned End Date changed from 31 Mar 2025 to 30 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com